title: [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
abstract: Chemotherapy administration to patients with lymphoproliferative diseases that are carriers of hepatitis B can be complicated by reactivation of Hepatitis B. This may lead to morbidity and mortality due to liver failure. We report 2 cases, treated recently. The first case is that of a 63-year-old female with a diagnosis of immunoblastic lymphoma. The patient was treated with the ProMACE-CytaBOM protocol. During treatment Hepatitis B was reactivated and after termination, of chemotherapy she developed fulminant hepatitis with hyperbilirubinemia, coagulopathy, hypoalbuminemia and ascites. The second case is that of a 34 years old male with a diagnosis of T-ALL who was treated according to the BFM 95 protocol. He had reactivation of Hepatitis B during induction therapy. These two patients were treated with Lamivudine with resolution of the hepatitis and disappearance of HBV DNA from the sera. Prophylactic administration of Lamivudine enabled reinduction of chemotherapy in the first case after relapse of the lymphoma and continuation of BFM 95 protocol in the second patient. Lamivudine inhibits replication of hepatitis B virus and prevents reactivation of Hepatitis B during immunosuppression induced by chemotherapy and probably ameliorates the severity of already reactivated hepatitis.
authors.forename: M
authors.initials: M
authors.lastname: Shtalrid
authors.forename: M
authors.initials: M
authors.lastname: Haran
authors.forename: A
authors.initials: A
authors.lastname: Klepfish
authors.forename: Y
authors.initials: Y
authors.lastname: Lurie
authors.forename: S
authors.initials: S
authors.lastname: Malnick
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000254:growth & development*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D018894:Reverse Transcriptase Inhibitors; D003561:Cytarabine; D001761:Bleomycin; D019259:Lamivudine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate